Isoprenaline Hydrochloride Macure (Isoprenaline Hydrochloride)

The drug stimulates beta‑1 receptors in the heart and beta‑2 receptors in the lungs. Activation of beta‑1 receptors raises cyclic AMP, increasing sinoatrial node activity, myocardial contractility, and conduction velocity. Beta‑2 receptor stimulation elevates cyclic AMP in bronchial smooth muscle, causing relaxation and bronchodilation.

The specific dose is determined by the prescribing clinician based on the patient’s condition, weight, and response. Typically, an intravenous infusion is started at a low rate and titrated upward until the desired heart rate or bronchodilatory effect is achieved, with continuous monitoring.

Safety data in pregnancy and lactation are limited. Use is generally reserved for situations where the therapeutic benefit outweighs potential risks to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and import documentation.

Isoprenaline is a non‑selective beta‑agonist, offering both cardiac and bronchodilatory effects. Compared with dopamine, which has dose‑dependent dopaminergic and adrenergic actions, isoprenaline provides more predictable heart‑rate acceleration but may cause greater tachycardia. Epinephrine has stronger alpha‑mediated vasoconstriction, whereas isoprenaline lacks significant vasoconstrictive activity.

Store the product at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and avoid freezing. Inspect the solution for particulate matter or discoloration before use and discard if any abnormalities are observed.

The medication is given intravenously, usually as a continuous infusion. The infusion rate is started at a low level and titrated according to the patient’s heart rate, blood pressure, and clinical response. Administration should occur under cardiac monitoring in a setting equipped for emergency intervention.

Serious adverse events include life‑threatening arrhythmias, myocardial ischemia, severe hypertension, pulmonary edema, and allergic reactions such as anaphylaxis. Prompt recognition and immediate discontinuation of the infusion, along with appropriate supportive measures, are essential when these events occur.

Isoprenaline is contraindicated in patients with uncontrolled tachyarrhythmias, severe hypertension, recent myocardial infarction, or known hypersensitivity to the drug. Caution is also advised for individuals with pheochromocytoma, hyperthyroidism, or those receiving non‑selective beta‑blockers.